The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical study of Dahuang-renshen decoction combined with modified DCF regimen chemotherapy on advanced gastric cancer
Author(s): 
Pages: 1008-1011
Year: Issue:  7
Journal: Hebei Journal of Traditional Chinese Medicine

Keyword:  DahuangRenshenGastric tumorAntineoplastic Combined Chemotherapy ProtocolsCombined therapy of Chinese and Western Medicine;
Abstract: 目的 观察大黄人参方联合改良DCF方案治疗晚期胃癌的临床疗效及安全性.方法 将64例晚期胃癌患者随机分为2组,治疗组32例子大黄人参方联合改良DCF化疗方案治疗,对照组32例予改良DCF方案化疗,21 d为1个化疗周期,所有患者致少接受2个周期化疗.观察2组客观疗效、生活质量、无进展生存期(PES)及不良反应.结果 治疗组临床获益率90.63%,优于对照组(66.67%,P<0.05);治疗组治疗后卡氏评分(KPS)好转率、食欲增加率及体质量增加率均高于对照组,差异均有统计学意义(P<0.05);治疗组PFS较对照组明显延长(P<0.05).治疗组Ⅰ~Ⅱ级主要毒副反应中自细胞计数减少、血小板计数减少、贫血、恶心、呕吐、周围神经毒性及肝功能损害发生率低于对照组(P<0.05).结论 大黄人参方联合改良DCF方案治疗晚期胃癌能提高临床获益率,提高生活质量,减轻化疗毒副反应,使患者更好耐受化疗.
Related Articles
No related articles found